MET and cancer: Further analysis revealed that the prognosis for cancer patients was independent of MET mutations in terms of progression-free survival (HR = 0.86; 95% CI, 0.70–1.04; P = 0.15; Fig. 2C) and overall survival (HR = 0.87; 95% CI, 0.71–1.07; P = 0.20; Fig. 2D).